Sarepta Therapeutics, Inc. Earnings

Sarepta Therapeutics, Inc.’s revenue jumped 40.79% since last year same period to $467.17Mn in the Q3 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 28.72% jump in its revenue since last 3-months.

Sarepta Therapeutics, Inc.’s net profit jumped 182.1% since last year same period to $33.61Mn in the Q3 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 420.29% jump in its net profits since last 3-months.

Sarepta Therapeutics, Inc.’s net profit margin jumped 158.32% since last year same period to 7.19% in the Q3 2024. On a quarterly growth basis, Sarepta Therapeutics, Inc. has generated 304.2% jump in its net profit margins since last 3-months.

Sarepta Therapeutics, Inc.’s price-to-earnings ratio after this Q3 2024 earnings stands at 73.84.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a -1400% fall from last quarter’s estimates.

Sarepta Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.13.

Sarepta Therapeutics, Inc.’s earning per share (EPS) jumped 173.91% since last year same period to 0.34 in the Q3 2024. This indicates that the Sarepta Therapeutics, Inc. has generated 173.91% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sarepta Therapeutics, Inc.’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sarepta Therapeutics, Inc.’s return on equity (ROE) stands at 0.12.